Andrea Valle

Andrea Valle

Auto-generated profile, based on publicly available information

Andrea Valle

San Raffaele Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2014 in Diabetes
Verified
Journal Article
Open access
PDF file
ACAntonio Citro
Antonio Citro
AVAndrea Valle
Andrea Valle
ECElisa Cantarelli
Elisa Cantarelli
AMAlessia Mercalli
Alessia Mercalli
SPSilvia Pellegrini
Silvia Pellegrini
LPLorenzo Piemonti
Lorenzo Piemonti
Chemokines and their receptors have been associated with or implicated in the pathogenesis of type 1 diabetes (T1D), but the identification of a single specific chemokine/receptor pathway that may constitute a suitable target for the development of therapeutic interventions is still lacking. Here, we used the multiple low doses (MLD)-streptozotocin (STZ) injection and the NOD mouse models to investigate the potency of CXCR1/2 inhibition to prevent inflammatory- and autoimmunity-mediated damage of pancreatic islets. Reparixin and ladarixin, non-competitive allosteric inhibitors, were used to obtain the pharmacologic blockade of CXCR1/2. Transient blockade of said receptors was effective in preventing inflammatory-mediated damage in MLD-STZ and in preventing and reverting diabetes in NOD mice. Blockade of CXCR1/2 was associated with insulitis inhibition and modification of leucocytes distribution in blood, spleen, bone marrow and lymph nodes. Among leucocytes, CXCR2+ myeloid cells were the most decreased subpopulations. All together these results propose CXCR1/2 chemokine receptors as “master regulators” of diabetes pathogenesis. The demonstration that this strategy may be successful in preserving the residual β-cells holds the potential to make a significant change in the approach to management of human T1D.